ANTI-PCSK1N (N-TERMINAL) ANTIBODY PRODU

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Pcsk1n may function in the control of the neuroendocrine secretory pathway. It is proposed to be a specific endogenous inhibitor of PCSK1. ProSAAS and Big PEN-LEN, both containing the C-terminal inhibitory domain, but not the processed peptides reduce PCSK1 activity in the endoplasmic reticulum and Golgi. It reduces the activity of the 87 kDa form but not the autocatalytically derived 65 kDa form of PCSK1. Subsequent processing of proSAAS may eliminate the inhibition. Slows down convertase-mediated processing of proopiomelanocortin and proenkephalin. Pcsk1n may control the intracellular timing of PCSK1 rather than its total level of activity.

Immunogen

Synthetic peptide directed towards the N-terminal region of Rat Pcsk1n

Physical form

Supplied at 0.5 mg/ml in phosphate-buffered saline, 0.09% sodium azide

Sequence

Synthetic peptide located within the following region: STPLRLRRAVPRGEAAGAVQELARALAHLLEAERQERARAEAQEAEDQQA